<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wu KF</submitter><funding>Dalin Tzu Chi Hospital</funding><pagination>20451253261419626</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905104</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Inadequate adherence to antipsychotic medication remains a major driver of relapse, hospitalization, and chronic disease progression in schizophrenia. Long-acting injectable (LAI) antipsychotics may reduce healthcare costs and the risk of relapse. However, evidence regarding the switch from paliperidone palmitate once every month (PP1M) to paliperidone palmitate once every 3 months (PP3M) remains limited.&lt;h4>Objectives&lt;/h4>To examine the utilization of LAI antipsychotics and investigate the effect of transitioning from PP1M to PP3M on adherence and healthcare utilization.&lt;h4>Design&lt;/h4>This retrospective, 12-month mirror-image study used nationwide, population-based data from Taiwan to examine changes in healthcare resource utilization and costs after the transition from</pubmed_abstract><journal>Therapeutic advances in psychopharmacology</journal><pubmed_title>Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based data.</pubmed_title><pmcid>PMC12905104</pmcid><funding_grant_id>DTCRD113-E-04</funding_grant_id><funding_grant_id>DTCRD110(2)-E-07</funding_grant_id><pubmed_authors>Yang YH</pubmed_authors><pubmed_authors>Wu KF</pubmed_authors><pubmed_authors>Tsai JH</pubmed_authors><pubmed_authors>Chuang HY</pubmed_authors><pubmed_authors>Hung CS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based data.</name><description>&lt;h4>Background&lt;/h4>Inadequate adherence to antipsychotic medication remains a major driver of relapse, hospitalization, and chronic disease progression in schizophrenia. Long-acting injectable (LAI) antipsychotics may reduce healthcare costs and the risk of relapse. However, evidence regarding the switch from paliperidone palmitate once every month (PP1M) to paliperidone palmitate once every 3 months (PP3M) remains limited.&lt;h4>Objectives&lt;/h4>To examine the utilization of LAI antipsychotics and investigate the effect of transitioning from PP1M to PP3M on adherence and healthcare utilization.&lt;h4>Design&lt;/h4>This retrospective, 12-month mirror-image study used nationwide, population-based data from Taiwan to examine changes in healthcare resource utilization and costs after the transition from</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026</publication><modification>2026-07-15T21:24:41.766Z</modification><creation>2026-07-09T10:14:08.719Z</creation></dates><accession>S-EPMC12905104</accession><cross_references><pubmed>41693796</pubmed><doi>10.1177/20451253261419626</doi></cross_references></HashMap>